Responses
Clinical/translational cancer immunotherapy
Original research
Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma
Compose a Response to This Article
Other responses
No responses have been published for this article.